Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
Maurie MarkmanUniversity of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: Both pre-clinical studies and phase 1–2 clinical trials have provided strong support for the potential role of regional drug delivery in the management of epithelial ovarian cancer, a disease proc...
Main Author: | Maurie Markman |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-02-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/intraperitoneal-chemotherapy-in-the-management-of-ovarian-cancer-focus-a2831 |
Similar Items
-
Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy
by: Laura Williams, et al.
Published: (2009-02-01) -
Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
by: Yin Tao, et al.
Published: (2022-03-01) -
Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020-11-01) -
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
by: Maurie Markman
Published: (2018-01-01) -
The effect of consolidation treatment with intraperitoneal carboplatin in advanced epithelial ovarian cancers
by: Azamsadat Mousavi, et al.
Published: (2014-07-01)